Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA KDM4B
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
siRNA KDM4B (KDM4B siRNA) is a small interfering RNA designed to target and silence the expression of lysine-specific demethylase 4B (KDM4B), an epigenetic enzyme that is frequently overexpressed in various malignancies, including breast and prostate cancers. KDM4B plays a critical role in cancer progression by acting as a co-activator for key transcription factors such as estrogen receptor alpha (ERα) and androgen receptor (AR). In laboratory research, siRNA KDM4B is widely utilized as a research-use-only (RUO) tool to knock down KDM4B expression, allowing investigators to study its impact on cell proliferation, cell-cycle progression, and metabolic reprogramming. Silencing KDM4B restores repressive histone marks (such as H3K9me3) and suppresses oncogenic signaling pathways, highlighting KDM4B as a promising therapeutic target.
- Other names
- KDM4B siRNAKDM-4B siRNAKDM 4B siRNAsiKDM4BsiKDM-4BsiKDM 4Bsmall interfering RNA targeting KDM4B
02
Targets
KDM4B
Beyond the preview
Go deeper on siRNA KDM4B.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA KDM4B.